News

Latest news

Hide mandatory notifications of trade

Researchers Find that Investigational Therapeutic HIV Vaccine, Vacc-4x, is still effective (Produces Immune Response) in HIV Study Volunteers Seven Years After Injection

31.05.2010 - Bionor Pharma’s subsidiary, Bionor Immuno AS completed a re-vaccination study at Norway’s largest hospital with Vacc-4x, the company’s most advanced HIV-vaccine candidate

 

(Oslo, Norway, 31 May 2010)  Bionor Pharma’s subsidiary, Bionor Immuno AS completed a re-vaccination study at Norway’s largest hospital with Vacc-4x, the company’s most advanced HIV-vaccine candidate. Twenty six of the forty HIV-patients from the 2002/03 phase IIa study were followed-up and re-vaccinated from January 2010-June 2010.

 

Promising Results:

Results from an analysis of blood samples taken prior to re-vaccination demonstrate that Vacc-4x is capable of creating immune cells with long-term memory. The study volunteers were observed more than 7 years after their initial immunization, and were found to have active immune cells with memory from the original immunization present. For about half of the patients, the results indicate that the immune system still combats HIV infected cells.

“These unprecedented findings further strengthen our confidence that Bionor’s vaccine technology will lead to a breakthrough in the way people living with HIV will be treated,” said Birger Sørensen, CEO, Bionor Immuno.  “Although long-term cell memory is a prerequisite for a working vaccine, it does not in itself demonstrate clinical effect.  But we’re cautiously confident that we’re succeeding where past attempts at therapeutic vaccines for HIV have failed.”

During the course of the re-vaccination study, further samples will be collected, analyzed and reported separately. The complete study will be published in more detail when full analysis has been made, following termination of the re-vaccination in June 2010.

 

Ongoing Placebo Controlled Study

In February 2008 Bionor initiated a phase II placebo controlled international (USA, UK, Germany, Italy and Spain) multicenter trial with 135 patients enrolled; results are expected in October 2010.

 

About Bionor Immuno

Bionor Immuno is an innovative biotech company developing pharmaceutical-grade peptide vaccines that stimulate cell-mediated immunity. Previous efforts within HIV-vaccines using T-cell stimulation have been unsuccessful, which is the reason they are not on the market today. Bionor Immuno carefully designs modified peptides with improved efficacy and safety profiles. HIV is the first disease targeted with the most advanced vaccine candidate in clinical phase IIb. However, Bionor Immuno’s platform technology is broadly applicable, and the company has vaccine candidates also for chronic infections such as Hepatitis C (HCV), Human Papilloma Virus (HPV) and Influenza. Bionor Immuno is a wholly owned subsidiary of Bionor Pharma ASA. Bionor Pharma ASA is listed on the Oslo Stock Exchange under the ticker symbol “NUT”, which soon will be changed to ”BIONOR”.

 

Contact information:

Trond Syvertsen, CEO Bionor Pharma ASA

+47 23 01 09 60

+47 91 72 14 57

 

Rolf Henning Lem, CFO Bionor Pharma ASA

+47 23 01 09 60

+47 97 74 88 45

 

Birger Sørensen

+47 404 07 565

+47 23 10 09 60

bs@bionorimmuno.com

Per Bengtsson

+46 734 474 128

pb@bionorimmuno.com

 

USA

David Sheon

202 547-2880

adc@bionorimmuno.com